Payment overview · 2025
General Payments
$794.20
44 reported records · 17 companies
Healthcare provider profile · identity verified
Anthony Sims, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HENAGAR, AL · NPI 1992786636
Verified facts
What the public records show
CMS Open Payments records show Anthony Sims, M.D. received $794.20 in general payments during 2025 across 44 reported records.
GlaxoSmithKline, LLC. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 346 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 346 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 316 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $172.34 | 21.7% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $152.60 | 19.2% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $71.15 | 9.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.81 | 8.0% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $50.26 | 6.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.69 | 4.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.91 | 4.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.10 | 4.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.07 | 3.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.48 | 3.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.17 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.89 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.82 | 2.6% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.00 | 2.5% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.62 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.01 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $9.28 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $794.20 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $131.12 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $104.94 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $99.96 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $71.15 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $70.77 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $67.40 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.81 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $52.92 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $50.26 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.69 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.07 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $9.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 316 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 178 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 346 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 155 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 44 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 112 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
178 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
346 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
44 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
112 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
346 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
205 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
155 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
316 | 47 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 1084 | 145 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 993 | 149 |
| Gabapentin | Gabapentin | 852 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 706 | 163 |
| Pantoprazole Sodium | Pantoprazole Sodium | 664 | 156 |
| Lisinopril | Lisinopril | 635 | 156 |
| Omeprazole | Omeprazole | 584 | 127 |
| Losartan Potassium | Losartan Potassium | 557 | 141 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 514 | 133 |
| Montelukast Sodium | Montelukast Sodium | 505 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 497 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 494 | 122 |
| Tramadol Hcl | Tramadol Hcl | 473 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 400 | 91 |
| Famotidine | Famotidine | 398 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 376 | 102 |
| Simvastatin | Simvastatin | 353 | 79 |
| Jardiance | Empagliflozin | 346 | 49 |
| Metformin Hcl | Metformin Hcl | 344 | 76 |
| Trazodone Hcl | Trazodone Hcl | 336 | 74 |
| Carvedilol | Carvedilol | 324 | 84 |
| Eliquis | Apixaban | 316 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 311 | 40 |
| Meloxicam | Meloxicam | 307 | 84 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 306 | 60 |
| Clonazepam | Clonazepam | 297 | 43 |
| Potassium Chloride | Potassium Chloride | 293 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 291 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 70 |
| Pioglitazone Hcl | Pioglitazone Hcl | 268 | 61 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 257 | 43 |
| Pregabalin | Pregabalin | 246 | 51 |
| Furosemide | Furosemide | 244 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 238 | 55 |
| Lorazepam | Lorazepam | 238 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 219 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 216 | 49 |
| Mounjaro | Tirzepatide | 205 | 37 |
| Prednisone | Prednisone | 202 | 106 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 48 |
| Sertraline Hcl | Sertraline Hcl | 197 | 44 |
| Farxiga | Dapagliflozin Propanediol | 178 | 31 |
| Glimepiride | Glimepiride | 169 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 58 |
| Ozempic | Semaglutide | 155 | 35 |
| Celecoxib | Celecoxib | 149 | 28 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 145 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 142 | 30 |
| Allopurinol | Allopurinol | 141 | 30 |
| Donepezil Hcl | Donepezil Hcl | 134 | 31 |
| Bupropion Xl | Bupropion Hcl | 131 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 130 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 128 | 33 |
| Spironolactone | Spironolactone | 125 | 26 |
| Metformin Hcl Er | Metformin Hcl | 123 | 33 |
| Azithromycin | Azithromycin | 114 | 104 |
| Irbesartan | Irbesartan | 113 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 28 |
| Aripiprazole | Aripiprazole | 103 | 11 |
| Sucralfate | Sucralfate | 102 | 28 |
| Januvia | Sitagliptin Phosphate | 101 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 99 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 98 | 21 |
| Temazepam | Temazepam | 98 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 93 | 74 |
| Estradiol | Estradiol | 93 | 21 |
| Finasteride | Finasteride | 85 | 18 |
| Xarelto | Rivaroxaban | 85 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 24 |
| Synthroid | Levothyroxine Sodium | 79 | 17 |
| Atenolol | Atenolol | 76 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 63 |
| Torsemide | Torsemide | 73 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 51 |
| Nebivolol Hcl | Nebivolol Hcl | 71 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 13 |
| Fluconazole | Fluconazole | 67 | 41 |
| Warfarin Sodium | Warfarin Sodium | 66 | 18 |
| Memantine Hcl | Memantine Hcl | 64 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 15 |
| Ondansetron Odt | Ondansetron | 62 | 35 |
| Amoxicillin | Amoxicillin | 60 | 45 |
| Entresto | Sacubitril/Valsartan | 57 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | 11 |
| Cefdinir | Cefdinir | 54 | 45 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 51 | 44 |
| Mupirocin | Mupirocin | 51 | 33 |
| Levofloxacin | Levofloxacin | 50 | 43 |
| Meclizine Hcl | Meclizine Hcl | 50 | 24 |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 49 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 48 | 30 |
| Ezetimibe | Ezetimibe | 47 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Fentanyl | Fentanyl | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 44 | 36 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Ibuprofen | Ibuprofen | 40 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 16 |
| Colchicine | Colchicine | 36 | 14 |
| Diazepam | Diazepam | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Topiramate | Topiramate | 36 | 11 |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Nabumetone | Nabumetone | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 32 | 13 |
| Alendronate Sodium | Alendronate Sodium | 31 | 12 |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 13 |
| Phenobarbital | Phenobarbital | 31 | suppressed |
| Valsartan | Valsartan | 31 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 28 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Nystatin | Nystatin | 26 | 19 |
| Primidone | Primidone | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 25 | suppressed |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 24 | suppressed |
| Dalfampridine Er | Dalfampridine | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Etodolac | Etodolac | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Lamotrigine Er | Lamotrigine | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Rybelsus | Semaglutide | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Prolia | Denosumab | 12 | 12 |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Mercaptopurine | Mercaptopurine | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $794.20 · 44 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, Auvelity, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, Kerendia, Korlym, LOREEV XR, NUPLAZID, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, SUBLOCADE, TRELEGY ELLIPTA, VRAYLAR | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error